Evidence map›Paper›PMID 31440705›Full record

ArticleKidney international reports2019

Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.

Clarissa Cassol, Anjali Satoskar, Gerard Lozanski, Brad Rovin, Lee Hebert, Tibor Nadasdy, Sergey V Brodsky

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Clarissa CassolDepartment of Pathology, The Ohio State University, Columbus, Ohio, USA.
Anjali SatoskarDepartment of Pathology, The Ohio State University, Columbus, Ohio, USA.
Gerard LozanskiDepartment of Pathology, The Ohio State University, Columbus, Ohio, USA.
Brad RovinDepartment of Medicine, The Ohio State University, Columbus, Ohio, USA.
Lee HebertDepartment of Medicine, The Ohio State University, Columbus, Ohio, USA.
Tibor NadasdyDepartment of Pathology, The Ohio State University, Columbus, Ohio, USA.
Sergey V BrodskyDepartment of Pathology, The Ohio State University, Columbus, Ohio, USA.
The Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNovel anticancer therapies include anti-programmed cell death protein-1 (PD-1) and anti-programmed death ligand-1 (PD-L1) drugs. These novel medications have side effects in different organs, including the kidney. The most common adverse effect in the kidney is acute interstitial nephritis (AIN). No diagnostic criteria are available to distinguish AIN associated with anti-PD-1 therapy from other AINs.

methodsKidney biopsy specimens from patients on anti-PD-1 therapy were stained with antibodies to PD-1 and PD-L1. Herein we report morphologic and immunohistochemical findings in 15 patients who received anti-PD-1 therapy and developed acute kidney injury requiring a kidney biopsy.

resultsAmong these patients, 9 had AIN and 6 had no AIN but showed acute tubular necrosis (ATN). Immunohistochemistry with antibodies to PD-1 and PD-L1 was performed on all of these biopsy specimens and on 9 randomly selected biopsy specimens with AIN from patients who did not receive anti-PD-1 medications, as well as 9 patients with lupus nephritis and active-appearing interstitial inflammation. There was weak staining for PD-1 in T cells in all patients with AIN and lupus; however, tubular epithelial cell membrane staining for PD-L1 was seen only in patients with anti-PD-1 therapy-associated AIN, and not in patients with anti-PD-1 therapy-associated ATN, and not in those with AIN secondary to other medications, or patients with lupus nephritis.

conclusionWe propose that immunohistochemistry with PD-L1 could be a useful tool to differentiate AIN associated with anti-PD-1 therapy from other AINs.

Indexed as

immunohistochemistryinterstitial nephritisPD-1 antagonistsrenal pathology

Identifiers

PMID31440705
PMCPMC6698303
OpenAlexW2950208654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.